Aids timeline
The major landmarks in the history of Aids, from its speculated beginnings in the 1920s to the present.
HIV infection rate 'stable'
The incidence of new HIV infections appears to have stabilised for the first time in the 25-year history of Aids.
Search News24
     South Africa : Aids Focus Get News24 on your mobile Terms & conditions 
Homepage
South Africa
News
Politics
Aids Focus
Power Crisis
Africa
World
Sport
Entertainment
Sci-Tech
Finance
Health
Galleries
 
Zimbabwe
Power Crisis
US Elections
Aids Focus
More...
 
MyNews24
Columnists
Sports Columnists
Feedback
 
National Lottery
UK Lottery
Travel
Competitions
Horoscopes
TV Guides
Classifieds
Super 14 game
 
Sudoku
Scrabble
Wacky Words
Word Cube
Creepy Crossword
Golf Solitaire
Battleship
 
Stidy
Urban Trash
Treknet
 
Newsletters
Weather

Cape Town:
16-20°C

Durban:
17-22°C

Johannesburg:
6-21°C

Weather Page

Traffic
Gauteng KwaZulu-Natal Eastern Cape Western Cape
All regions
Indicators
Rand/$ 7.6100
Rand/£ 14.8500
Rand/€ 11.7900
Gold/oz $882.30
Gold Mining 2531.38
+0.00%
All-share index 32145.49
+0.00%
 
Afrikaans
English
 

TAC says price drop not enough
28/04/2003 22:01  - (SA)  

  • Firm slashes Aids drug prices
  • Firm slashes Aids drug prices
  • TAC members in court
  • TAC members in court
  • TAC takes aim at Mbeki
  • TAC takes aim at Mbeki
  • New Aids drugs are rays of hope
  • 'Glaxo fiddles while SA burns'
  • Johannesburg - Insufficient is how the Treatment Action Campaign views the announcement by pharmaceutical giant GlaxoSmithKline that it will cut the prices of its HIV/Aids drugs by up to 47% for countries eligible for reduced prices.

    The reduction will drop the price of Combivir, an HIV/Aids treatment recommended by the World Health Organisation, to 90 cents a day in 63 developing countries, including South Africa.

    The pharmaceutical company announced it would also reduce the price of Epivir, commonly known at 3TC and Retrovir, also known as AZT, by 45% and 38% respectively.

    TAC spokesperson Nathan Geffen said on Monday the price reduction was not being made available to pharmacies which was where most patients got their medication.

    "Only about 1 000 people get their medication through the public-health system. Most people get their medication in the private sector."

    Geffen said the only way to keep prices substantially low was through generic competition.

    Pressure from around the world

    He said GlaxoSmithKline also needed to clarify if it was going to lower the price of Lamibudine. Combivir is made up of AZT and Lamibudine.

    "Often doctors want to prescribe the Lamibudine without the AZT. Lamibudine is excessively priced. Are they going to lower its price?"

    Geffen said Glaxo had not lowered the prices because "they were nice people", but because of pressure brought on them by activists around the world.

    "This pressure cannot be maintained forever. We need to introduce generic competition," he said.

    He said while Glaxo's action was insufficient, the positive side was that the drugs were being offered to employers who were treating their workers who were not part of medical-aid plans.

     
     



    About us | Advertise | Contact us | Job opportunities | Press Releases | Site map

    Back to top
     Sponsored links
    Life Insurance
    Car Insurance
    UK Lottery
    First for Women
    Your Homeloan
    Bid or Buy
    Medical Aid
    Education
    SA TV online
    Car Rental
    Credit cards
    Personal Loans
    Best Car Deals
    Compare Quotes
    Life Insurance for Women